Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 16/20 | 0.70 |
| ▸ | EDNRB | P24530 | 2/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712331 | 0.93 | MAPK8 (0.61) | MAPK8EDNRBEDNRAMAPK9MAPK10 | |
| SCHEMBL4709845 | 0.92 | MAPK8 (0.74) | MAPK8MAPK9MAPK10ALDH1A1LMNA | |
| SCHEMBL4710877 | 0.92 | MAPK8 (0.67) | MAPK8MAPK9MAPK10MEN1KMT2A | |
| SCHEMBL4710291 | 0.91 | MAPK8 (0.69) | MAPK8MAPK9MAPK10 | |
| SCHEMBL1518799 | 0.91 | MAPK8 (0.66) | MAPK8MAPK9MAPK10MEN1KMT2A | |
| SCHEMBL4709441 | 0.91 | MAPK8 (0.75) | MAPK8MAPK9MAPK10MEN1KMT2A | |
| SCHEMBL1518849 | 0.91 | MAPK8 (0.75) | MAPK8MAPK9MAPK10 | |
| SCHEMBL7381016 | 0.89 | MAPK8 (0.55) | MAPK8EDNRBEDNRAALDH1A1MAPK1 | |
| SCHEMBL4710235 | 0.89 | MAPK8 (0.57) | MAPK8MAPK9MAPK10MEN1KMT2A | |
| SCHEMBL4711612 | 0.88 | MAPK8 (0.58) | MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | MAPK8 5/4885EDNRB 2740/4885EDNRA 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.